Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Перспективные направления нейропротекции при ишемическом инсульте в эксперименте и клинике
________________________________________________
Kotov S.V., Isakova E.V., Sidorova O.P., Belova Yu.A. Prospective experimental and clinical trends of neuroprotection in ischemic stroke. Consilium Medicum. 2016; 18 (9): 45–48. DOI: 10.26442/2075-1753_2016.9.45-48
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: инсульт, ишемический каскад, нейропротекция, нейроваскулярная единица, протеин, фактор роста.
________________________________________________
Key words: stroke, ischemic cascade, neuroprotection, neurovascular unit, protein, growth factor.
2. Espinosa de Rueda M, Parrilla G, Manzano-Fernández S et al. Combined multimodal computed tomography score correlates with futile recanalization after thrombectomy in patients with acute stroke. Stroke 2015; 46 (9): 2517–22. Doi: 10.1161/STROKEAHA.114.008598.
3. Gomis M, Dávalos A. Recanalization and reperfusion therapies of acute ischemic stroke: what have we learned, what are the major research questions, and wh ere are we headed? Front Neurol 2014; 5: 226. Doi: 10.3389/fneur.2014.00226. eCollection 2014.
4. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 2007; 61 (5): 396–402.
5. Fisher M, Feuerstein G, Howells DW et al. STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40 (6): 2244–50. Doi: 10.1161/STROKEAHA.108.541128.
6. Vivien D, Gauberti M, Montagne A et al. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab 2011; 31 (11): 2119–34. Doi: 10.1038/jcbfm.2011.127.
7. Broussalis E, Trinka E, Killer M et al. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies. Drug Discov Today 2012; 17 (13–14): 671–84. Doi: 10.1016/j.drudis.2012.02.011.
8. O'Collins VE, Macleod MR, Donnan GA, Howells DW. Evaluation of combination therapy in animal models of cerebral ischemia. J Cereb Blood Flow Metab 2012; 32 (4): 585–97. Doi: 10.1038/jcbfm.2011.203.
9. Wang Y, Zhang ZG, Rhodes K et al. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007; 151 (8): 1377–84.
10. Solaroglu I, Cahill J, Tsubokawa T et al. Granulocyte colony-stimulating factor protects the brain against experimental stroke via inhibition of apoptosis and inflammation. Neurol Res 2009; 31 (2): 167–72. Doi: 10.1179/174313209X393582.
11. Yang J, Guo L, Liu R, Liu H. Neuroprotective effects of VEGF administration after focal cerebral ischemia/reperfusion: dose response and time window. Neurochem Int 2012; 60 (6): 592–6. Doi: 10.1016/j.neuint.2012.02.020.
12. Белова Ю.А., Чуксина Ю.Ю., Шевелев С.В. и др. Уровень эндотелиальных прогениторных клеток у больных с ишемическим инсультом и эффективность реабилитации. Альманах клин. медицины. 2015; 39: 45–50. / Belova Iu.A., Chuksina Iu.Iu., Shevelev S.V. i dr. Uroven' endotelial'nykh progenitornykh kletok u bol'nykh s ishemicheskim insul'tom i effektivnost' reabilitatsii. Al'manakh klin. meditsiny. 2015; 39: 45–50. [in Russian]
13. Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today 2012; 48 (Suppl. A): 3–24. Doi: 10.1358/dot.2012.48 (Suppl. A).1739716.
14. Zhang L, Chopp M, Meier DH et al. Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke. Stroke 2013; 44: 1965–72. Doi: 10.1161/ STROKEAHA.111.000831.
15. Felling RJ, Song H. Epigenetic mechanisms of neuroplasticity and the implications for stroke recovery. Exp Neurol 2015; 268: 37–45. Doi: 10.1016/j.expneurol.2014.09.017.
16. Heiss WD, Brainin M, Bornstein NM et al. Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 2012; 43 (3): 630–6. Doi: 10.1161/STROKEAHA.111.628537.
17. Lang W, Stadler CH, Poljakovic Z, Fleet D. Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke 2013; 8 (2): 95–104. Doi: 10.1111/j.1747-4949.2012.00901.x.
18. Muresanu DF, Heiss WD, Hoemberg V et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke 2016; 47 (1): 151–9. Doi: 10.1161/STROKEAHA.115.009416.
19. Lyle RC. A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int J Rehabil Res 1981; 4: 483–92. Doi: 10.1097/00004356-198112000-00001.
20. Garg R, Chaudhuri A, Munschauer F, Dandona P. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke 2006; 37 (1): 267–73.
21. Huang SS, Lu YJ, Huang JP et al. The essential role of endothelial nitric oxide synthase activation in insulin-mediated neuroprotection against ischemic stroke in diabetes. J Vasc Surg 2014; 59 (2): 483–91. Doi: 10.1016/j.jvs.2013.03.023.
22. Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: more than just a peripheral hormone. J Aging Re 2012; 2012: 384017. Doi: 10.1155/2012/384017.
23. Lioutas VA, Novak V. Intranasal insulin neuroprotection in ischemic stroke. Neural Regen Res 2016; 11 (3): 400–1. Doi: 10.4103/1673-5374.179040.
24. Zhu H, Zhang Y, Shi Z et al. The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways. Sci Rep 2016; 6: 26859. Doi: 10.1038/srep26859.
25. Campbell BC, Christensen S, Tress BM et al. EPITHET Investigators. Failure of collateral blood flow is associated with infarct growth in ischemic stroke. J Cereb Blood Flow Metab 2013; 33 (8): 1168–72. Doi: 10.1038/jcbfm.2013.77.
26. Shuaib A, Butcher K, Mohammad AA et al. Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet Neurol 2011; 10 (10): 909–21. Doi: 10.1016/S1474-4422(11)70195-8.
27. Cuccione E, Padovano G, Versace A et al. Cerebral collateral circulation in experimental ischemic stroke. Exp Transl Stroke Med 2016; 8: 2. Doi: 10.1186/s13231-016-0015-0.eCollection 2016.
________________________________________________
1. Powers WJ, Derdeyn CP, Biller J et al. American Heart Association Stroke Council. 2015 AHA/ASA focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals fr om the American heart association/American stroke association. Stroke 2015; 46 (10): 3020–35. Doi:10.1161/STR.0000000000000074.
2. Espinosa de Rueda M, Parrilla G, Manzano-Fernández S et al. Combined multimodal computed tomography score correlates with futile recanalization after thrombectomy in patients with acute stroke. Stroke 2015; 46 (9): 2517–22. Doi: 10.1161/STROKEAHA.114.008598.
3. Gomis M, Dávalos A. Recanalization and reperfusion therapies of acute ischemic stroke: what have we learned, what are the major research questions, and wh ere are we headed? Front Neurol 2014; 5: 226. Doi: 10.3389/fneur.2014.00226. eCollection 2014.
4. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 2007; 61 (5): 396–402.
5. Fisher M, Feuerstein G, Howells DW et al. STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40 (6): 2244–50. Doi: 10.1161/STROKEAHA.108.541128.
6. Vivien D, Gauberti M, Montagne A et al. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab 2011; 31 (11): 2119–34. Doi: 10.1038/jcbfm.2011.127.
7. Broussalis E, Trinka E, Killer M et al. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies. Drug Discov Today 2012; 17 (13–14): 671–84. Doi: 10.1016/j.drudis.2012.02.011.
8. O'Collins VE, Macleod MR, Donnan GA, Howells DW. Evaluation of combination therapy in animal models of cerebral ischemia. J Cereb Blood Flow Metab 2012; 32 (4): 585–97. Doi: 10.1038/jcbfm.2011.203.
9. Wang Y, Zhang ZG, Rhodes K et al. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007; 151 (8): 1377–84.
10. Solaroglu I, Cahill J, Tsubokawa T et al. Granulocyte colony-stimulating factor protects the brain against experimental stroke via inhibition of apoptosis and inflammation. Neurol Res 2009; 31 (2): 167–72. Doi: 10.1179/174313209X393582.
11. Yang J, Guo L, Liu R, Liu H. Neuroprotective effects of VEGF administration after focal cerebral ischemia/reperfusion: dose response and time window. Neurochem Int 2012; 60 (6): 592–6. Doi: 10.1016/j.neuint.2012.02.020.
12. Belova Iu.A., Chuksina Iu.Iu., Shevelev S.V. i dr. Uroven' endotelial'nykh progenitornykh kletok u bol'nykh s ishemicheskim insul'tom i effektivnost' reabilitatsii. Al'manakh klin. meditsiny. 2015; 39: 45–50. [in Russian]
13. Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today 2012; 48 (Suppl. A): 3–24. Doi: 10.1358/dot.2012.48 (Suppl. A).1739716.
14. Zhang L, Chopp M, Meier DH et al. Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke. Stroke 2013; 44: 1965–72. Doi: 10.1161/ STROKEAHA.111.000831.
15. Felling RJ, Song H. Epigenetic mechanisms of neuroplasticity and the implications for stroke recovery. Exp Neurol 2015; 268: 37–45. Doi: 10.1016/j.expneurol.2014.09.017.
16. Heiss WD, Brainin M, Bornstein NM et al. Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 2012; 43 (3): 630–6. Doi: 10.1161/STROKEAHA.111.628537.
17. Lang W, Stadler CH, Poljakovic Z, Fleet D. Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke 2013; 8 (2): 95–104. Doi: 10.1111/j.1747-4949.2012.00901.x.
18. Muresanu DF, Heiss WD, Hoemberg V et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke 2016; 47 (1): 151–9. Doi: 10.1161/STROKEAHA.115.009416.
19. Lyle RC. A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int J Rehabil Res 1981; 4: 483–92. Doi: 10.1097/00004356-198112000-00001.
20. Garg R, Chaudhuri A, Munschauer F, Dandona P. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke 2006; 37 (1): 267–73.
21. Huang SS, Lu YJ, Huang JP et al. The essential role of endothelial nitric oxide synthase activation in insulin-mediated neuroprotection against ischemic stroke in diabetes. J Vasc Surg 2014; 59 (2): 483–91. Doi: 10.1016/j.jvs.2013.03.023.
22. Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: more than just a peripheral hormone. J Aging Re 2012; 2012: 384017. Doi: 10.1155/2012/384017.
23. Lioutas VA, Novak V. Intranasal insulin neuroprotection in ischemic stroke. Neural Regen Res 2016; 11 (3): 400–1. Doi: 10.4103/1673-5374.179040.
24. Zhu H, Zhang Y, Shi Z et al. The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways. Sci Rep 2016; 6: 26859. Doi: 10.1038/srep26859.
25. Campbell BC, Christensen S, Tress BM et al. EPITHET Investigators. Failure of collateral blood flow is associated with infarct growth in ischemic stroke. J Cereb Blood Flow Metab 2013; 33 (8): 1168–72. Doi: 10.1038/jcbfm.2013.77.
26. Shuaib A, Butcher K, Mohammad AA et al. Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet Neurol 2011; 10 (10): 909–21. Doi: 10.1016/S1474-4422(11)70195-8.
27. Cuccione E, Padovano G, Versace A et al. Cerebral collateral circulation in experimental ischemic stroke. Exp Transl Stroke Med 2016; 8: 2. Doi: 10.1186/s13231-016-0015-0.eCollection 2016.
ГБУЗ МО Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского. 129110, Россия, Москва, ул. Щепкина, д. 61/2
*kotovsv@yandex.ru
________________________________________________
M.F.Vladimirskiy Moscow regional research clinical institute. 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2
*kotovsv@yandex.ru